Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Net Margin (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Net Margin for 4 consecutive years, with 507.77% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 42126.0% to 507.77% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1115.27% through Dec 2025, down 4365.0% year-over-year, with the annual reading at 1115.27% for FY2025, 4365.0% down from the prior year.
  • Net Margin hit 507.77% in Q4 2025 for Taysha Gene Therapies, up from 1353.58% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 628962.5% in Q1 2022 to a low of 2467.07% in Q3 2023.
  • Historically, Net Margin has averaged 41996.52% across 4 years, with a median of 705.39% in 2024.
  • Biggest five-year swings in Net Margin: crashed -62933696bps in 2023 and later surged 103955bps in 2024.
  • Year by year, Net Margin stood at 4220.54% in 2022, then tumbled by -69bps to 1324.67% in 2023, then crashed by -170bps to 929.03% in 2024, then surged by 45bps to 507.77% in 2025.
  • Business Quant data shows Net Margin for TSHA at 507.77% in Q4 2025, 1353.58% in Q2 2025, and 935.23% in Q1 2025.